OTC · BSEM
Healthcare · Biotechnology
$3.10
Down-$0.70 (-18.42%)
Updated Aug 14, 2026, 6:23 AM
SID Score
2.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
BSEM does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning BSEM.
BSEM research
Company profile and research snapshot.
BIOSTEM TECHNOLOGIES NEW
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 7, 2022 | Zacks Investment Research | Buy | — |
No generated briefing is available yet.
Benzinga · Aug 13, 2026
Gainers Liminatus Pharma (NASDAQ:LIMN) stock increased by 48.4% to $0.16 during Thursday's regular session. The market value of their outstanding shares is at $7.2 million. BeyondSpring (NASDAQ:BYSI) shares moved
SeekingAlpha · Aug 12, 2026
BioStem Technologies, Inc. (BSEM) Q2 2026 Earnings Call August 12, 2026 4:30 PM EDTCompany ParticipantsPhilip Taylor - AssociateJason Matuszewski - CEO,...
Benzinga · Aug 12, 2026
BioStem Technologies (NASDAQ:BSEM) reported quarterly losses of $(0.52) per share. The company reported $7.899 million in sales this quarter. This is a 27.95 percent decrease over sales of $10.963 million the same
Benzinga · Aug 6, 2026
BioStem Technologies Inc. (OTC:BSEM) ("BioStem" or the "Company"), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning BSEM.
No results
No recent SID articles mention BSEM.
